News

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. This is the company’s second approval to start a Phase

The open-label trial (Study 204) is designed to evaluate the safety of eteplirsen over 96 weeks of dosing, and will be conducted in DMD patients who are non-ambulant

Neuren intends to submit applications to the US Food and Drug Administration (FDA) for both Orphan Drug and Breakthrough Therapy designation. Neuren expects to meet with the FDA

Capstone has been created through the integration of H.I.G. portfolio companies Integrity Nutraceuticals in Spring Hill, TN and Cornerstone Research & Development in Ogden, UT. Capstone will compete

Rociletinib is the Company’s novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in

The transaction was announced on September 29, 2014 and included upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock, and additional contingent consideration

Irenas of the United States District Court for the District of New Jersey in the patent infringement lawsuit filed by Horizon against Watson Laboratories, Inc. for an Abbreviated

Severe aplastic anaemia is a rare disorder in which the bone marrow fails to make enough new blood cells. Currently, there are no approved therapies available for SAA

Following approval for the IND application, the company will conduct a Phase I/II trial of ADXS-HPV alone or in combination with MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736,